Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577].

Autor: Huelse JM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA., Fridlyand DM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA., Earp S; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., DeRyckere D; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA., Graham DK; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA. Electronic address: Douglas.Graham@choa.org.
Jazyk: angličtina
Zdroj: Pharmacology & therapeutics [Pharmacol Ther] 2021 Sep; Vol. 225, pp. 107822. Date of Electronic Publication: 2021 Mar 10.
DOI: 10.1016/j.pharmthera.2021.107822
Databáze: MEDLINE
Externí odkaz: